



## Total Voting Rights

August 2, 2021

RNS Number : 2696H

Renalytix PLC

02 August 2021

**Renalytix plc**  
("Renalytix" or the "Company")

### Total voting rights

**New York, 2 August 2021** - Renalytix (LSE: RENX) announces that the Company's total issued share capital consists of 72,229,786 shares of 0.25 pence each, with each share carrying the right to one vote. Renalytix does not hold any shares in treasury. The total number of voting rights in the Company following Admission will therefore be 72,229,786.

The figure of 72,229,786 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company, under the FCA's Disclosure and Transparency Rules.

***For further information, please contact:***

**Renalytix plc**

James McCullough, CEO

[www.renalytix.com](http://www.renalytix.com)

**Via Walbrook PR**

**Stifel (Nominated Adviser, Joint Broker)**

Alex Price / Nicholas Moore

**Tel: 020 7710 7600**

**Investec Bank plc (Joint Broker)**

Gary Clarence / Daniel Adams

**Tel: 020 7597 4000**

**Walbrook PR Limited**

Paul McManus / Lianne Cawthorne

**Tel: 020 7933 8780** or [renalytix@walbrookpr.com](mailto:renalytix@walbrookpr.com)

**Mob: 07980 541 893 / 07584 391 303**

### About Kidney Disease

Kidney disease is now recognized as a public health epidemic affecting over 850 million people globally. The Centers for Disease Control and Prevention (CDC) estimates that 15% of US adults, or 37 million people, currently have chronic kidney disease (CKD). Further, the CDC reports that 9 out of 10 adults with CKD do not know they have it and one out of two people with very low kidney

function who are not on dialysis do not know they have CKD.<sup>1</sup> Kidney disease is referred to as a "silent killer" because it often has no symptoms and can go undetected until a very advanced stage. Each year kidney disease kills more people than breast and prostate cancer. Every day, 13 patients in the United States die while waiting for a kidney transplant.

#### **About KidneyIntelX**

KidneyIntelX, is a first-of-kind, bioprognostic™ platform that employs a proprietary artificial intelligence-enabled algorithm to combine diverse data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record, or EHR, systems, to generate a unique patient risk score. This patient risk score enables prediction of progressive kidney function decline in chronic kidney disease, or CKD, allowing physicians and healthcare systems to optimize the allocation of treatments and clinical resources to patients at highest risk.

#### **About Renalytix**

Renalytix (LSE: REX) (NASDAQ: RNLX) is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. The Company's lead product is KidneyIntelX, which has been granted Breakthrough Designation by the U.S. Food and Drug Administration and which is being designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery (visit [www.kidneyintelx.com](http://www.kidneyintelx.com)). For more information, visit [www.renalytix.com](http://www.renalytix.com).

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@lseg.com](mailto:rns@lseg.com) or visit [www.rns.com](http://www.rns.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

TVRDKBBPKBKDFFK